Benitec Biopharma INC

Benitec Biopharma appoints David Friedman to the Board of Directors while CFO Megan Boston rotates off the Board.

Benitec Biopharma announced Q3 2026 financial results and provided an operational update highlighting positive interim clinical data for its BB-301 gene therapy candidate for OPMD.

Benitec Biopharma announced its Q2 2026 financial results and positive clinical data for its OPMD gene therapy candidate, BB-301, showing durable efficacy.

Benitec Biopharma Inc. announced that its stockholders approved all proposals, including director elections and executive compensation, at the 2025 Annual Meeting.

Benitec Biopharma announced positive interim Phase 1b/2a trial results for BB-301, achieving a 100% responder rate, securing FDA Fast Track Designation, and completing a $100 million public offering.

Benitec Biopharma Inc. announced the pricing of a combined underwritten public offering and registered direct offering, expecting to raise approximately $100 million in gross proceeds.

Benitec Biopharma Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing progress in its OPMD therapeutic development and financial position.

Benitec Biopharma Inc. reported positive long-term clinical results for its lead OPMD gene therapy candidate, BB-301, alongside a significant capital raise, bolstering its financial position.

Benitec Biopharma Inc. announced positive interim clinical results for its BB-301 OPMD treatment, securing FDA Fast Track designation, alongside a significant $100 million capital raise.

Benitec Biopharma extends its Hayward, California lease through December 2027 and reports positive interim clinical trial data for its BB-301 OPMD treatment.

Benitec Biopharma's Q2 2025 report details financial results and provides updates on the clinical development of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD).

Benitec Biopharma's Q1 2025 report highlights positive interim clinical trial data for its OPMD treatment, BB-301, alongside a significant increase in cash reserves due to warrant exercises.

Benitec Biopharma Inc. filed an amended annual report for fiscal year 2025 to include auditor signatures and updated certifications, while reporting increased cash and continued operational losses.

Benitec Biopharma Inc. restated prior period financial statements due to share-based compensation errors, while continuing to advance its lead OPMD gene therapy, BB-301, through clinical trials.

Benitec Biopharma Inc. has filed its annual 10-K report, highlighting advancements in its OPMD treatment program and financial activities.

Director J. Kevin Buchi reported a disposition of 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised charitable fund.

Director David Matthew Friedman was granted 35,000 stock options as part of his board compensation at Benitec Biopharma.

Benitec Biopharma Inc. Director Sharon Mates was granted 31,500 stock options with an exercise price of $12.83, set to vest by December 1, 2026.

Suvretta Capital Management and its affiliated funds significantly increased their beneficial ownership in Benitec Biopharma Inc. through open market purchases.

Suvretta Capital Management and its affiliated funds increased their beneficial ownership in Benitec Biopharma Inc. through multiple open market purchases in December 2025.

Benitec Biopharma Inc. Director Edward F. Smith was granted 35,000 stock options with an exercise price of $12.23, which will vest by December 1, 2026.

Benitec Biopharma Inc. announced the appointment of Dr. Sharon Mates to its Board of Directors, increasing the board size to seven members.

Benitec Biopharma Inc. announced the details for its Annual Stockholder Meeting on December 1, 2025, including director elections and key proposals.

Benitec Biopharma Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 1, 2025, to vote on director elections, auditor ratification, and executive compensation.

Benitec Biopharma's Compensation Committee approved discretionary bonus payments for its Executive Chairman/CEO and Executive Director for their performance during the fiscal year ending June 30, 2024.

Benitec Biopharma is holding its annual stockholder meeting on December 4, 2024, to vote on director elections, ratification of the accounting firm, executive compensation, and authorization of preferred stock.

Benitec Biopharma Inc. will hold its annual shareholder meeting on December 4, 2024, to vote on director elections, ratification of the accounting firm, executive compensation, and an amendment to authorize additional preferred stock.

Benitec Biopharma is registering for resale 32,871,201 shares of common stock to satisfy registration rights granted in connection with a recent $40 million private placement.

Benitec Biopharma Inc. completed a registered direct offering with Averill Master Fund and Averill Madison Master Fund, selling common stock and granting registration rights for resale.

Suvretta Capital Management and its affiliated funds, Averill Master Fund and Averill Madison Master Fund, have significantly increased their beneficial ownership in Benitec Biopharma Inc. to 49.9% following a registered direct offering.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. reported beneficial ownership of 10.6% of Benitec Biopharma Inc.'s common stock, including shares from warrants.

Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Benitec Biopharma Inc. common stock.

RA Capital Management and its affiliates have disclosed a 5.5% beneficial ownership stake in Benitec Biopharma Inc., holding 1,850,000 shares of common stock.

Franklin Resources, Inc. and its affiliates updated their beneficial ownership in Benitec Biopharma Inc. to 14.9% of common stock.

Janus Henderson Group plc and its affiliate have reported a significant beneficial ownership stake of 11.3% in Benitec Biopharma Inc. common stock.

Janus Henderson Group plc and its affiliates have reported an aggregate beneficial ownership of 11.3% in Benitec Biopharma Inc.'s common stock.